EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave", or the "Company")
today announced that the Company has signed a Commercial Royalty-Bearing License
(the "License") and Machine Purchase Agreement (the "Agreement") with Sutro
Biopharma ("Sutro"), a company based in San Francisco that has developed a
proprietary biochemical protein synthesis technology. Sutro has licensed
EnWave's Radiant Energy Vacuum ("REV(TM)") dehydration technology to dehydrate
cell-free extract for their protein synthesis process.


Sutro has been working with EnWave's lab-scale powderREV(R) technology to
generate dried cell-free extract since September 2012. After validating the
efficacy and stability of cell-free extract after REV(TM) dehydration, Sutro
secured the global right to use REV(TM) technology and thereby enable larger
scale processing of its cell-free extract to support pharmaceutical product
development and commercialization.


In addition to the License, Sutro will fund development at EnWave of a new
prototype powderREV(R) machine and will conduct a series of process optimization
tests. If the final tests are consistent with the previously documented results,
Sutro has an option to purchase a commercial-scale powderREV(R) machine at an
agreed, undisclosed sales price.


"We are very encouraged by the results obtained from our preliminary evaluation
of EnWave's REV(TM) technology," stated Mr. William Newell, chief executive
officer of Sutro Biopharma. "The powderREV(R) machine will enable us to
dehydrate cell-free extracts, which will simplify storage conditions and may
improve product stability. The next stage of testing and development will be
very important if we are to achieve broad, meaningful commercialization."


Tim Durance, Ph.D., chairman and co-CEO of EnWave, commented, "Sutro is led by a
team of very experienced life science professionals that share a collective
vision of transforming protein therapeutics by short-cutting the development and
manufacturing sequence. We are pleased our first commercial license in the
pharmaceutical sector is associated with a promising new technology with such
potentially high growth prospects."


About Sutro Biopharma

Sutro Biopharma, located in South San Francisco, is developing a new generation
of multi-functional antibody drug conjugate combination therapeutics and
bifunctional antibody-based therapeutics for targeted cancer therapies. Sutro's
biochemical synthesis technology, which underpins these therapeutics, allows the
rapid and systematic exploration of many protein drug variants to research,
discover and develop drug candidates. Sutro's make-test cycle for hundreds of
protein variants, including those incorporating non-natural amino acids, takes
approximately two weeks. Once identified, these protein drug candidates are
rapidly and predictably manufactured at commercial scales. In addition to
developing its own drug pipeline, Sutro Biopharma is collaborating with select
pharmaceutical and biotech companies in the research, discovery, development,
and manufacture of novel protein therapeutics. For more information on Sutro
Biopharma please visit www.sutrobio.com.


About EnWave

EnWave Corporation is a Vancouver-based industrial technology company developing
commercial applications for its proprietary Radiant Energy Vacuum (REV(TM))
dehydration technology. EnWave aims to sign royalty-bearing commercial licenses
with leading food and pharmaceutical companies for the use of its revolutionary
technology. Thus far the Company has signed commercial licenses with Bonduelle,
a global leader in the production of vegetables, for the processing of
dehydrofrozen vegetables; Hormel Food Corporation, a major processed meat
manufacturer, for the production of healthy dried meat products; Milne Fruit
Product, EnWave's first major licensee, for the production of several dehydrated
fruit and vegetable products in the whole, fragmented and powdered form; a
leading North American enzyme company, to dehydrate a series of food-related
enzymes for their Tier 1 clients; and Napa Mountain Spice Company, to dry
high-quality California bay leaves. In addition to these licenses, EnWave has
formed a Limited Liability Partnership with Lucid Capital Management to develop,
manufacture, market and sell all-natural cheese snack products in the United
States under the Moon Cheese(R) brand and NutraDried Creations to market cheese
and other REV(TM) snack products through private label distribution channels in
the United States and Latin America. Most recently, EnWave signed a commercial
royalty-bearing license with NutraDried Creations LLP to enable them to
aggressively market nutritious snack products to private label customers in
North America and Latin America and a commercial license with a Canadian
vegetable and herb producer.


Also, EnWave has entered into a wide range of research and collaboration
agreements with an expanding list of multinational companies, including Nestle,
Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray Cranberries, Cherry Central,
Sun-Maid Growers, Gay Lea Foods, R.J. Reynolds and Merck. EnWave is introducing
REV(TM) as a new dehydration standard in the food and biological material
sectors: potentially faster and cheaper than freeze drying, with better end
product quality than air drying or spray drying.


EnWave currently has six REV(TM) platforms: commercial-scale nutraREV(R) and
MIVAP(R) are used in the food industry to dry fruits, vegetables, meat, herbs
and seafood quickly and at low-cost, while maintaining high levels of nutrition,
taste, texture and colour. The Company is also developing powderREV(R) for bulk
dehydration of food cultures, probiotics and fine biochemicals such as enzymes;
quantaREV(TM) for continuous, high-volume low-temperature drying of pastes,
gels, liquids, or particulates; and bioREV(TM) and freezeREV(TM) as new methods
to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies.
More information about EnWave is available at www.enwave.net.


EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's strategy
for growth, product development, market position, expected expenditures, and the
expected synergies following the closing are forward-looking statements. All
third party references to market information in this release are not guaranteed
to be accurate as the Company did not conduct the original primary research.
These statements are not a guarantee of future performance and involve a number
of risks, uncertainties and assumptions. Although the Company has attempted to
identify important factors that could cause actual results to differ materially,
there may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ materially from
those anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
EnWave Corporation
Mr. John McNicol
President & Co-CEO
(604)601-8524
john.mcnicol@enwave.net


EnWave Corporation
Mr. Brent Charleton
Vice President, Corporate Affairs
(778)378-9616
bcharleton@enwave.net
www.enwave.net
EnWave (TSXV:ENW)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more EnWave Charts.
EnWave (TSXV:ENW)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more EnWave Charts.